Occult persistence and lymphotropism of hepatitis C virus infection

World Journal of Gastroenterology

Volumn 14, Issue 18, 2008, Pages 2789-2793

  Pham, Tram N Q ^a   Michalak, Tomasz I ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

Chronic hepatitis C; Consequences of occult HCV persistence; HCV lymphotropism; Hepatitis C virus; Occult viral persistence

Indexed keywords

ALPHA INTERFERON; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS RNA;

B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CULTURE; EDITORIAL; GENE SEQUENCE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOLOGICAL TOLERANCE; LIVER TRANSPLANTATION; LYMPHOCYTE TRANSFORMATION; LYMPHOID CELL; MICROFLORA; MONOCYTE; NONHUMAN; OCCULT HEPATITIS C; PERSISTENT VIRUS INFECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; SERODIAGNOSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; T LYMPHOCYTE SUBPOPULATION; VIROGENESIS; VIRUS GENOME; VIRUS HEPATITIS; VIRUS REPLICATION;

EID: 48049093273     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.2789     Document Type: Editorial

References (40)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576
2. Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, Marinos G, Kaldor JM. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34: 809-816
3. Brass V, Moradpour D, Blum HE. Molecular virology of hepatitis C virus (HCV): 2006 update. Int J Med Sci 2006; 3: 29-34
4. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-1171
5. Kamal SM, El Tawil AA, Nakano T, He Q, Rasenack J, Hakam SA, Saleh WA, Ismail A, Aziz AA, Madwar MA. Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut 2005; 54: 858-866
6. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982
7. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965
8. Michalak TI, Pham TNQ, Mulrooney-Cousins PM. Molecular diagnosis of occult hepatitis C and hepatitis B virus infections. Future Virol 2007; 2: 451-465
9. Pham TN, MacParland SA, Mulrooney PM, Cooksley H, Naoumov NV, Michalak TI. Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol 2004; 78: 5867-5874
10. Radkowski M, Gallegos-Orozco JF, Jablonska J, Colby TV, Walewska-Zielecka B, Kubicka J, Wilkinson J, Adair D, Rakela J, Laskus T. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology 2005; 41: 106-114
11. Castillo I, Rodriguez-Inigo E, Lopez-Alcorocho JM, Pardo M, Bartolome J, Carreno V. Hepatitis C virus replicates in the liver of patients who have a sustained response to antiviral treatment. Clin Infect Dis 2006; 43: 1277-1283
12. Di Liberto G, Roque-Afonso AM, Kara R, Ducoulombier D, Fallot G, Samuel D, Feray C. Clinical and therapeutic implications of hepatitis C virus compartmentalization. Gastroenterology 2006; 131: 76-84
13. Pham TN, Mulrooney-Cousins PM, Mercer SE, MacParland SA, Inglot M, Zalewska M, Simon K, Michalak TI. Antagonistic expression of hepatitis C virus and alpha interferon in lymphoid cells during persistent occult infection. J Viral Hepat 2007; 14: 537-548
14. Pham TN, King D, Macparland SA, McGrath JS, Reddy SB, Bursey FR, Michalak TI. Hepatitis C virus replicates in the same immune cell subsets in chronic hepatitis C and occult infection. Gastroenterology 2008; 134: 812-822
15. Ciancio A, Smedile A, Giordanino C, Colletta C, Croce G, Pozzi M, Cariti G, Macor A, Biglino A, Di Napoli A, Tappero GF, Andreoni M, Manca A, Prandi G, Calleri G, Orsi PG, Ciccone G, Rizzetto M, Saracco G. Long-term follow-up of previous hepatitis C virus positive nonresponders to interferon monotherapy successfully retreated with combination therapy: are they really cured? Am J Gastroenterol 2006; 101: 1811-1816
16. Castillo I, Pardo M, Bartolome J, Ortiz-Movilla N, Rodriguez-Inigo E, de Lucas S, Salas C, Jimenez-Heffernan JA, Perez-Mota A, Graus J, Lopez-Alcorocho JM, Carreno V. Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. J Infect Dis 2004; 189: 7-14
17. Bartolome J, Lopez-Alcorocho JM, Castillo I, Rodriguez-Inigo E, Quiroga JA, Palacios R, Carreno V. Ultracentrifugation of serum samples allows detection of hepatitis C virus RNA in patients with occult hepatitis C. J Virol 2007, 81: 7710-7715
18. Carreno V. Occult hepatitis C virus infection: a new form of hepatitis C. World J Gastroenterol 2006; 12: 6922-6925
19. Blackard JT, Kemmer N, Sherman KE. Extrahepatic replication of HCV: insights into clinical manifestations and biological consequences. Hepatology 2006; 44: 15-22
20. Pham TN, Michalak TI. Occult hepatits C virus persistence: identification and characteristics. MLO Med Lab Obs 2006; 38: 20-22
21. Radkowski M, Wilkinson J, Nowicki M, Adair D, Vargas H, Ingui C, Rakela J, Laskus T. Search for hepatitis C virus negative-strand RNA sequences and analysis of viral sequences in the central nervous system: evidence of replication. J Virol 2002; 76: 600-608
22. Oldstone MB. Virus-lymphoid cell interactions. Proc Natl Acad Sci USA 1996; 93: 12756-12758
23. Ciurea A, Klenerman P, Hunziker L, Horvath E, Odermatt B, Ochsenbein AF, Hengartner H, Zinkernagel RM. Persistence of lymphocytic choriomeningitis virus at very low levels in immune mice. Proc Natl Acad Sci USA 1999; 96: 11964-11969
24. Michalak TI. Occult persistence and lymphotropism of hepadnaviral infection: insights from the woodchuck viral hepatitis model. Immunol Rev 2000; 174: 98-111
25. Agnello V, De Rosa FG. Extrahepatic disease manifestations of HCV infection: some current issues. J Hepatol 2004; 40: 341-352
26. Matsuo K, Kusano A, Sugumar A, Nakamura S, Tajima K, Mueller NE. Effect of hepatitis C virus infection on the risk of non-Hodgkin's lymphoma: a meta-analysis of epidemiological studies. Cancer Sci 2004; 95: 745-752
27. Pham TN, Macparland SA, Coffin CS, Lee SS, Bursey FR, Michalak TI. Mitogen-induced upregulation of hepatitis C virus expression in human lymphoid cells. J Gen Virol 2005; 86: 657-666
28. Ducoulombier D, Roque-Afonso AM, Di Liberto G, Penin F, Kara R, Richard Y, Dussaix E, Feray C. Frequent compartmentalization of hepatitis C virus variants in circulating B cells and monocytes. Hepatology 2004; 39: 817-825
29. MacParland SA, Pham TN, Gujar SA, Michalak TI. De novo infection and propagation of wild-type Hepatitis C virus in human T lymphocytes in vitro. J Gen Virol 2006; 87: 3577-3586
30. Nakajima N, Hijikata M, Yoshikura H, Shimizu YK. Characterization of long-term cultures of hepatitis C virus. J Virol 1996; 70: 3325-3329
31. Cramp ME, Carucci P, Rossol S, Chokshi S, Maertens G, Williams R, Naoumov NV. Hepatitis C virus (HCV) specific immune responses in anti-HCV positive patients without hepatitis C viraemia. Gut 1999; 44: 424-429
32. Quiroga JA, Llorente S, Castillo I, Rodriguez-Inigo E, Lopez-Alcorocho JM, Pardo M, Carreno V. Virus-specific T cell responses associated with hepatitis C virus (HCV) persistence in the liver after apparent recovery from HCV infection. J Med Virol 2006; 78: 1190-1197
33. Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, Miller JL, Manns MP, Rehermann B. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000; 6: 578-582
34. Quiroga JA, Llorente S, Castillo J, Rodriguez-Inigo E, Pardo M, Carreno V. Cellular immune responses associated with occult hepatitis C virus infection of the liver. J Virol 2006; 80: 10972-10979
35. Bain C, Fatmi A, Zoulim F, Zarski JP, Trepo C, Inchauspe G. Impaired allostimulatory functions of dendritic cells in chronic hepatitis C patients. Gastroenterology 2001; 120: 512-524
36. Caserta MT, McDermott MP, Dewhurst S, Schnabel K, Carnahan JA, Gilbert L, Lathan G, Lofthus GK, Hall CB. Human herpesvirus 6 (HHV6) DNA persistence and reactivation in healthy children. J Pediatr 2004; 145: 478-484
37. Lee WM, Polson JE, Carney DS, Sahin B, Gale M Jr. Reemergence of hepatitis C virus after 8.5 years in a patient with hypogammaglobulinemia: evidence for an occult viral reservoir. J Infect Dis 2005; 192: 1088-1092
38. Forns X, Garcia-Retortillo, M, Serrano T, FeliuSuarez F, de la Mata M, Garcia-Valdecasas JC, Navasa M, Rimola A, Rodes J. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003; 39: 389-396
39. Melon S, Galarraga MC, Villar M, Laures A, Boga JA, de Ona M, Gomez E. Hepatitis C virus reactivation in anti-hepatitis C virus positive renal transplant recipients. Transplant Proc 2005; 37: 2083-2085
40. Zekri AR, Mohamed WS, Samra MA, Sherif GM, El-Shehaby AM, El-Sayed MH. Risk factors for cytomegalovirus, hepatitis B and C virus reactivation after bone marrow transplantation. Transpl Immunol 2004; 13: 305-311